Avelumab

證據等級: L5

預測適應症: 10 個

Avelumab: Evaluation Report — Insufficient Data for Full Repurposing Analysis

One-Sentence Summary

Avelumab (DrugBank: DB11945) is a fully human anti-PD-L1 monoclonal antibody checkpoint inhibitor currently not approved in Taiwan. This Evidence Pack contains no TxGNN predicted indications, and critical data fields — including original indication, mechanism of action, and safety profile — are absent. A Hold decision is recommended until the data gaps identified below are resolved.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	No TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction unavailable; no supporting studies retrievable
Taiwan Market Status	✗ Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, this section cannot be completed. The Evidence Pack does not include original indication data (original_indications: []) or mechanism of action information (original_moa: [Data Gap]), and the predicted_indications array is empty.

DrugBank query (Query Log ID 3) confirmed one record exists for Avelumab in DrugBank, but the parsed content was not forwarded into the Evidence Pack. Retrieving the full DrugBank entry — including pharmacology, targets, and categories — is a prerequisite before any mechanistic rationale can be constructed.

Clinical Trial Evidence

Currently no predicted indication is available to associate clinical trials with. Clinical trial evidence retrieval is deferred pending TxGNN prediction output.

Literature Evidence

Currently no predicted indication is available to associate literature with. Literature retrieval is deferred pending TxGNN prediction output.

Taiwan Market Information

Avelumab has no approved authorizations in Taiwan. The TFDA query (Query Log ID 1) returned zero results.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert query (Query Log ID 4) returned 1 result, indicating a package insert document may exist. The parsed safety content — warnings, contraindications, and drug interactions — was not populated into this Evidence Pack. Drug interaction query (Query Log ID 2) returned no results.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is structurally incomplete — no predicted indications, no original indication records, no MOA, and no safety data are present. A repurposing evaluation cannot be performed without these inputs.

To proceed, the following is needed:

[Blocking — DG001] Parse TFDA package insert PDF to extract contraindications and key warnings; this is required before any safety screening (S1 gate)
[High — DG002] Retrieve full Avelumab entry from DrugBank API to populate mechanism of action, pharmacological targets, and drug categories
[Required] Run TxGNN prediction pipeline for Avelumab (DB11945) to generate predicted_indications with disease scores, clinical trial links, and literature references
[Required] Confirm original approved indication(s) from DrugBank or TFDA package insert to anchor the repurposing comparison
[Recommended] After MOA is confirmed, verify whether Avelumab meets antineoplastic/cytotoxic criteria to determine if a Cytotoxicity section is required in the final report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.